A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04544410 |
|
Recruitment Status :
Recruiting
First Posted : September 10, 2020
Last Update Posted : March 11, 2022
|
Sponsor:
Spruce Biosciences
Information provided by (Responsible Party):
Spruce Biosciences
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Congenital Adrenal Hyperplasia | Drug: Tildacerfont/Placebo | Phase 2 |
This is a study that will evaluate the ability of Tildacerfont to reduce the glucocorticoid steroid dose used by adult CAH subjects. The first 24-weeks will be a double-blind, placebo controlled, comparison of Tildacerfont vs Placebo. The following 52-weeks will allow all subjects to move to open label Tildacerfont to continue to reduce steroid dose where appropriate, and observe long term safety.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 90 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Subjects will be randomized in a 1:1 manner to either Tildacerfont or Placebo. |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Masking Description: | Double-Blind |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects With Classic Congenital Adrenal Hyperplasia |
| Actual Study Start Date : | September 29, 2020 |
| Estimated Primary Completion Date : | June 2022 |
| Estimated Study Completion Date : | November 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency
21-hydroxylase deficiency
17 alpha-hydroxylase/17,20-lyase deficiency
3-beta-hydroxysteroid dehydrogenase deficiency
MedlinePlus related topics:
Steroids
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Tildacerfont Group
Tildacerfont administered daily via oral tablet for 76 weeks at dose level 1.
|
Drug: Tildacerfont/Placebo
Tablet, administered daily
Other Name: SPR001 |
|
Placebo Comparator: Placebo
Placebo administered daily via oral tablet for 24 weeks.
|
Drug: Tildacerfont/Placebo
Tablet, administered daily
Other Name: SPR001 |
Primary Outcome Measures :
- Change in GC dose at Week 24 [ Time Frame: 24 Weeks ]Absolute change from baseline in GC dose in HCe at Week 24
Secondary Outcome Measures :
- Change in GC use adjusted for body surface area in subjects with CAH [ Time Frame: 24 weeks ]Absolute change from baseline in GC dose in HCe in mg/m2
- Change in the median cumulative HCe dose in subjects with CAH [ Time Frame: 76 Weeks ]Median total cumulative GC dose in HCe
- Change in GC use while maintaining control of A4 in subjects with CAH [ Time Frame: 24 Weeks ]
Composite endpoint:
Absolute change from baseline in GC dose in HCe in subjects who maintain A4 ≤ ULN
- Change in supraphysiologic GC use to physiologic GC use while maintaining control of A4 in subjects with CAH [ Time Frame: 24 Weeks ]
Composite endpoint:
Proportion of subjects with GC dose ≤20 mg/day in HCe in subjects who maintain A4 ≤ ULN
- Change in GC toxicity in subjects with CAH [ Time Frame: 24 weeks ]
Glucocorticoid Toxicity Index Aggregate Improvement Score (GTI-AIS) (Miloslavsky 2017)
Score range: -346 to 439 A positive score means worsening and a negative score means improvement
- Change in metabolic parameters (fat mass) in subjects with CAH [ Time Frame: 24 weeks ]Change from baseline in fat mass as measured by dual-energy X-ray absorptiometry (DXA)
- Change in metabolic parameters (body weight) in subjects with CAH [ Time Frame: 24 weeks ]Change from baseline in body weight
- Change in metabolic parameters (homeostatic model assessment of insulin resistance) in subjects with CAH [ Time Frame: 24 weeks ]Change from baseline in homeostatic model assessment of insulin resistance (HOMA-IR)
Other Outcome Measures:
- Change in acne in patients with CAH with acne at baseline [ Time Frame: 24 weeks ]Change from baseline in Investigator's Global Assessment (IGA) score, a 5 point scale with 0 being a better outcome
- Change in acne in patients with CAH with acne at baseline [ Time Frame: 24 weeks ]Change from baseline in Subject Numerical Rating Scale (NRS) for acne, an 11-point scale ranging from 0 to 10 with 0 being a better outcome
- Change in hirsutism in female CAH subjects with hirsutism at baseline [ Time Frame: 24 weeks ]Change from baseline in Modified Ferriman-Gallwey (mFG) score a 5 point scale with 0 being a better outcome Numerical Rating Scale (NRS) for hirsutism
- Change in hirsutism in female CAH subjects with hirsutism at baseline [ Time Frame: 24 weeks ]Change from baseline in Subject Numerical Rating Scale (NRS) for acne, an 11-point scale ranging from 0 to 10 with 0 being a better outcome
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and female subjects over 18 years old, inclusive
- Has a documented historical diagnosis of classic CAH due to 21-hydroxylase deficiency based on genetic mutation in CYP21A2 and/or elevated 17-OHP
- Has been on a stable, supraphysiologic dose of GC replacement for ≥1 month before screening without any evidence of non-adherence to the GC regimen during this period.
- For subjects with the salt-wasting form of CAH, subject has been on a stable dose of mineralocorticoid replacement for ≥1 month before screening
Exclusion Criteria:
- Has a known or suspected diagnosis of any other known form of classic CAH (not due to 21-hydroxylase deficiency)
- Has a history that includes bilateral adrenalectomy or hypopituitarism
- Has a history of allergy or hypersensitivity to tildacerfont, any of its excipients, or any other CRF1 receptor antagonist
- Shows clinical signs or symptoms of adrenal insufficiency
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04544410
Contacts
| Contact: Clinical Trials | 415-655-4169 | CAH_ClinicalTrials@sprucebiosciences.com |
Locations
Show 44 study locations
Sponsors and Collaborators
Spruce Biosciences
Investigators
| Principal Investigator: | Ron Newfield, M.D | Rady Children's Hospital-San Diego and Professor of clinical pediatrics at UC San Diego School of Medicine. |
Additional Information:
| Responsible Party: | Spruce Biosciences |
| ClinicalTrials.gov Identifier: | NCT04544410 |
| Other Study ID Numbers: |
SPR001-204 CAHmelia 204 ( Other Identifier: Spruce Biosciences ) |
| First Posted: | September 10, 2020 Key Record Dates |
| Last Update Posted: | March 11, 2022 |
| Last Verified: | March 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Spruce Biosciences:
|
CAH Adrenal Disorder Congenital Adrenal Hyperplasia |
Additional relevant MeSH terms:
|
Adrenal Hyperplasia, Congenital Adrenogenital Syndrome Adrenocortical Hyperfunction Hyperplasia Pathologic Processes Disorders of Sex Development Urogenital Abnormalities Congenital Abnormalities |
Genetic Diseases, Inborn Steroid Metabolism, Inborn Errors Metabolism, Inborn Errors Metabolic Diseases Adrenal Gland Diseases Endocrine System Diseases Gonadal Disorders |